Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/182977
Title: Extracellular Vesicles Derived from Plasmodium-infected and Non-infected Red Blood Cells as Targeted Drug Delivery Vehicles
Author: Borgheti Cardoso, Livia Neves
Kooijmans, Sander A. A.
Gutiérrez Chamorro, Lucía
Biosca, Arnau
Lantero, Elena
Ramírez, Miriam
Avalos Padilla, Yunuen
Crespo, Isabel
Fernandez Vidal, Irene
Fernández Becerra, Carmen
Portillo Obando, Hernando A. del
Fernàndez Busquets, Xavier
Keywords: Malària
Hematies
Malaria
Erythrocytes
Issue Date: 2020
Publisher: Elsevier
Abstract: Among several factors behind drug resistance evolution in malaria is the challenge of administering overall doses that are not toxic for the patient but that, locally, are sufficiently high to rapidly kill the parasites. Thus, a crucial antimalarial strategy is the development of drug delivery systems capable of targeting antimalarial compounds to Plasmodium with high specificity. In the present study, extracellular vesicles (EVs) have been evaluated as a drug delivery system for the treatment of malaria. EVs derived from naive red blood cells (RBCs) and from Plasmodium falciparum-infected RBCs (pRBCs) were isolated by ultrafiltration followed by size exclusion chromatography. Lipidomic characterization showed that there were no significant qualitative differences between the lipidomic profiles of pRBC-derived EVs (pRBC-EVs) and RBC-derived EVs (RBC-EVs). Both EVs were taken up by RBCs and pRBCs, although pRBC-EVs were more efficiently internalized than RBC-EVs, which suggested their potential use as drug delivery vehicles for these cells. When loaded into pRBC-EVs, the antimalarial drugs atovaquone and tafenoquine inhibited in vitro P. falciparum growth more efficiently than their free drug counterparts, indicating that pRBC-EVs can potentially increase the efficacy of several small hydrophobic drugs used for the treatment of malaria.
Note: Versió postprint del document publicat a: http://dx.doi.org/ 10.1016/j.ijpharm.2020.119627
It is part of: International Journal of Pharmaceutics, 2020, vol 587, num.119627
URI: http://hdl.handle.net/2445/182977
Related resource: http://dx.doi.org/ 10.1016/j.ijpharm.2020.119627
ISSN: 0378-5173
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB))
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Files in This Item:
File Description SizeFormat 
Postprint_Fernandez-Busquets_X_Int_J_Pharm_2020.pdf663.06 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.